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Tamsulosin for patients  
with ureteral stones? 
Yes, but only for some. Find out which of your patients 
can benefit.
PRACTICE CHANGER
Prescribe tamsulosin for stone expulsion in 
patients with distal ureteral stones 5 to 10 mm 
in size.1
STRENGTH OF RECOMMENDATION
A: Based on a meta-analysis of randomized 
controlled trials.
Wang RC, Smith-Bindman R, Whitaker E, et al. Effect of tamsulosin on 
stone passage for ureteral stones: a systematic review and meta-analy-
sis. Ann Emerg Med. 2017;69:353-361.
ILLUSTRATIVE CASE
A 54-year-old man presents to the emergency 
department (ED) with acute onset left flank 
pain that radiates to the groin. A computed 
tomography (CT) scan of the abdomen/- 
pelvis without contrast reveals a 7-mm dis-
tal ureteral stone. He is deemed appropri-
ate for outpatient management. In addition 
to pain medications, should you prescribe 
tamsulosin?
According to the most recent National Health and Nutrition Examination Survey, the population prevalence 
of kidney stones is 8.8% with a self-reported 
prevalence in men of 10.6% and a self- 
reported prevalence in women of 7.1%.2 
Most ureteral stones can be treated in the 
outpatient setting with oral hydration, anti-
emetics, and pain control with nonsteroidal 
anti-inflammatory medications as first-line 
treatment and opioids as a second-line op-
tion.3 In addition, alpha-blockers are used for 
medical expulsive therapy (MET). In fact, the 
European Association of Urology guideline 
on urolithiasis states that MET may acceler-
ate passage of ureteral stones.3   
Recently, however, uncertainty has 
surrounded the effectiveness of the alpha-
blocker tamsulosin. Two systematic reviews, 
limited by heterogeneity because some of the 
studies lacked a placebo control and blind-
ing, concluded that alpha-blockers increased 
stone passage within one to 6 weeks when 
compared with placebo or no additional ther-
apy.4,5 However, a recent large multicenter, 
randomized controlled trial (RCT) revealed 
no difference between tamsulosin and nife-
dipine or either one compared with placebo 
at decreasing the need for further treatment 
to achieve stone passage within 4 weeks.6 
STUDY SUMMARY
New meta-analysis breaks down results 
by stone size
This meta-analysis by Wang et al, consist-
ing of 8 randomized, double-blind, placebo-
controlled trials of adult patients (N=1384), 
examined the effect of oral tamsulosin 
0.4 mg/d (average of a 28-day course) on 
distal ureteral stone passage.1 A subgroup 
analysis comparing stone size (<5 mm and 
5-10 mm) was also conducted to determine if 
stone size modified the effect of tamsulosin. 
Although the initial search included 
studies published between 1966 and 2015, 
the 8 that were eventually analyzed were 
published between 2009 and 2015, were 
conducted in multiple countries (and in-
cluded regardless of language), and were 
conducted in ED and outpatient urology set-
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tings. The main outcome measure was the 
risk difference in stone passage between the 
tamsulosin group and placebo group after 
follow-up imaging at 3 weeks with CT or plain 
film radiographs. 
❚ Tamsulosin helps some, but not all. 
The pooled risk of stone passage was higher 
in the tamsulosin group than in the placebo 
group (85% vs 66%; risk difference [RD]=17%; 
95% confidence interval [CI], 6%-27%), but 
significant heterogeneity existed across the 
trials (I2=80.2%). After subgroup analysis by 
stone size, the researchers found that tam-
sulosin was beneficial for larger stones, 5 to 
10 mm in size (6 trials, N=514; RD=22%; 95% 
CI, 12%-33%; number needed to treat=5), 
compared with placebo, but not for smaller 
stones, <5 mm in size (4 trials, N=533; RD= 
-0.3%; 95% CI, -4% to 3%). The measure of 
heterogeneity in the 5- to 10-mm subgroup 
demonstrated a less heterogeneous popu-
lation of studies (I2=33%) than that for the 
<5-mm subgroup (I2=0%). 
❚ In terms of adverse events, tamsu-
losin did not increase the risk of dizziness 
(RD=.2%; 95% CI, -2.1% to 2.5%) or postural 
hypotension (RD=.1%; 95% CI, -0.4% to 0.5%) 
compared with placebo. 
WHAT’S NEW
Passage of larger stones 
increases with tamsulosin
This meta-analysis included only random-
ized, double-blind, placebo-controlled trials. 
Prior meta-analyses did not. Also, this review 
included the SUSPEND (Spontaneous Urinary 
Stone Passage Enabled by Drugs) trial, an RCT 
discussed in a previous PURL (Kidney stones? 
It’s time to rethink those meds. J Fam Pract. 
2016;65:118-120.) that recommended against 
the alpha-blockers tamsulosin and nifedipine 
for ureteral stones measuring <10 mm.6,7 
But the subgroup analysis in this more 
recent review went one step further in the 
investigation of tamsulosin’s effect by ex-
amining passage rates by stone size (<5 mm 
vs 5-10 mm) and revealing that passage of 
larger stones (5-10 mm) increased with tam-
sulosin. The different results based on stone 
size may explain the recent uncertainty as 
to whether tamsulosin improves the rate of 
stone passage. 
CAVEATS
Study doesn’t address proximal,  
or extra-large stones
Only distal stones were included in 7 of the 
8 trials. Thus, this meta-analysis was unable 
to determine the effect on more proximal 
stones. Also, it’s unclear if the drug provides 
any benefit with stones >10 mm in size. 
CHALLENGES TO IMPLEMENTATION
None worth mentioning
We see no challenges to implementation of 
this recommendation.                   JFP
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